Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Insider Greg Keenan Sells 12,239 Shares

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) insider Greg Keenan sold 12,239 shares of Aurinia Pharmaceuticals stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $8.00, for a total transaction of $97,912.00. Following the sale, the insider now owns 161,789 shares in the company, valued at approximately $1,294,312. This represents a 7.03 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Aurinia Pharmaceuticals Price Performance

Shares of Aurinia Pharmaceuticals stock opened at $8.67 on Thursday. The company has a current ratio of 5.60, a quick ratio of 5.11 and a debt-to-equity ratio of 0.17. The company’s 50-day moving average price is $8.13 and its two-hundred day moving average price is $7.86. Aurinia Pharmaceuticals Inc. has a 52 week low of $4.71 and a 52 week high of $10.67. The stock has a market cap of $1.24 billion, a PE ratio of -57.80 and a beta of 1.22.

Analysts Set New Price Targets

Separately, StockNews.com cut shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, February 19th.

Institutional Investors Weigh In On Aurinia Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of AUPH. Segall Bryant & Hamill LLC raised its position in Aurinia Pharmaceuticals by 1.6% in the third quarter. Segall Bryant & Hamill LLC now owns 562,775 shares of the biotechnology company’s stock worth $4,125,000 after acquiring an additional 9,031 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new stake in Aurinia Pharmaceuticals in the third quarter worth about $3,330,000. Intech Investment Management LLC purchased a new position in Aurinia Pharmaceuticals in the 3rd quarter worth about $262,000. Charles Schwab Investment Management Inc. increased its stake in Aurinia Pharmaceuticals by 13.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 744,050 shares of the biotechnology company’s stock worth $5,454,000 after purchasing an additional 89,940 shares in the last quarter. Finally, FMR LLC increased its stake in Aurinia Pharmaceuticals by 44.8% in the 3rd quarter. FMR LLC now owns 12,673 shares of the biotechnology company’s stock worth $93,000 after purchasing an additional 3,919 shares in the last quarter. 36.83% of the stock is currently owned by institutional investors.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.